MLICM
URGN icon

Metropolitan Life Insurance Company (MetLife)’s UroGen Pharma URGN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,586
Closed -$23.8K – 2011
2024
Q1 		$23.8K Hold
1,586
– – ﹤0.01% 1774
2023
Q4 		$23.8K Buy
1,586
+508
+47% +$6.59K ﹤0.01% 1837
2023
Q3 		$15.1K Hold
1,078
– – ﹤0.01% 2026
2023
Q2 		$11.2K Buy
+1,078
New +$11.9K ﹤0.01% 2241
2021
Q4 		– Sell
-5,563
Closed -$93.6K – 2829
2021
Q3 		$93.6K Buy
+5,563
New +$88.2K ﹤0.01% 2561
2021
Q2 		– Sell
-6,091
Closed -$119K – 2886
2021
Q1 		$119K Hold
6,091
– – ﹤0.01% 2346
2020
Q4 		$110K Hold
6,091
– – ﹤0.01% 2311
2020
Q3 		$117K Hold
6,091
– – ﹤0.01% 2126
2020
Q2 		$159K Sell
6,091
-726
-11% -$17.7K ﹤0.01% 1959
2020
Q1 		$122K Hold
6,817
– – ﹤0.01% 1907
2019
Q4 		$227K Sell
6,817
-410
-6% -$11.2K ﹤0.01% 1828
2019
Q3 		$172K Buy
+7,227
New +$236K ﹤0.01% 1983

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s URGN Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of UroGen Pharma (URGN) in Q2 2024, closing a stake of 1,586 shares — an estimated $23.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in URGN in Q3 2019 and held it in 12 quarters. The position peaked at $227K in Q4 2019. 115 funds tracked by Wall St. Rank hold URGN as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining UroGen Pharma position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,586 UroGen Pharma shares in Q2 2024, an estimated $23.8K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in UroGen Pharma in Q3 2019 and held it in 12 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s UroGen Pharma position peaked at $227K in Q4 2019.
  • 115 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.